GSK plc with ticker (LON:GSK) now has a potential downside of -4.2% according to JP Morgan.
JP Morgan set a target price of 1,660 GBX for the company, which when compared to the GSK plc share price of 1,733 GBX at opening today (03/05/2024) indicates a potential downside of -4.2%. Trading has ranged between 1,303 (52 week low) and 1,743 (52 week high) with an average of 5,117,084 shares exchanging hands daily. The market capitalisation at the time of writing is £71,443,796,655.
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
GSK plc -4.2% potential downside indicated by JP Morgan
- Written by: Charlotte Edwards
Latest Company News
GSK says Japan has expanded Arexvy eligibility to adults aged 18–49 at increased risk of RSV disease, including immunocompromised patients.
GSK has entered an exclusive collaboration with SBP Group’s CTTQ unit to accelerate the launch of bepirovirsen, a potential first-in-class chronic hepatitis B treatment currently under priority review in China.
The approval covers Blenrep plus bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma and is supported by phase III DREAMM-7 data showing progression-free and overall survival benefits.
GSK has closed its acquisition of 35Pharma, gaining HS235, a potential treatment for pulmonary hypertension that targets the activin receptor signalling pathway and is expected to enter proof-of-concept trials soon.
The NMPA has approved Exdensur for adults with chronic rhinosinusitis with nasal polyps, based on phase III data showing improved nasal polyp and obstruction scores, with tolerability similar to placebo.
GSK said China’s National Medical Products Administration approved Exdensur (depemokimab) for severe eosinophilic asthma in adults and adolescents aged 12 and older, supported by phase III data showing sustained exacerbation reduction versus placebo.
